AstraZeneca to Unveil its Robust Pipeline of Breast Cancer at SABCS
Shots:
- AstraZeneca will divulge new developments across BC at the 2020 SABCS. The key abstract includes data of P-ll DESTINY-Breast01 study reinforcing the efficacy seen with Enhertu in HER2+ mBC following 2+ prior anti-HER2 based regimens
- The company will present data of P-I SERENA-1 study demonstrating the efficacy & safety of AZD9833 as a monothx. and in combination with the palbociclib in HR+- HER2- negative advanced BC
- AstraZeneca will present RWE to understand outcomes for patients with germline BRCA mutations and treatment patterns among patients with HER2+ mBC. The company will also showcase data on the role of AI & digital pathology in measuring levels of HER2 expression in patients with BC
Ref: AstraZeneca | Image: New Europe
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com